Commonwealth Equity Services LLC Has $616,000 Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Commonwealth Equity Services LLC lowered its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 20.4% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,537 shares of the company’s stock after selling 7,056 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Intellia Therapeutics were worth $616,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. First Horizon Advisors Inc. increased its stake in Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after purchasing an additional 472 shares in the last quarter. Interchange Capital Partners LLC increased its position in Intellia Therapeutics by 6.5% in the 1st quarter. Interchange Capital Partners LLC now owns 10,909 shares of the company’s stock valued at $303,000 after buying an additional 670 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Intellia Therapeutics by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company’s stock worth $245,000 after buying an additional 750 shares during the period. Axxcess Wealth Management LLC raised its stake in Intellia Therapeutics by 6.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 16,602 shares of the company’s stock worth $457,000 after buying an additional 1,010 shares during the period. Finally, Intellectus Partners LLC boosted its holdings in Intellia Therapeutics by 2.1% in the second quarter. Intellectus Partners LLC now owns 58,225 shares of the company’s stock worth $1,303,000 after acquiring an additional 1,225 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Stifel Nicolaus decreased their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $61.77.

Intellia Therapeutics Stock Up 1.8 %

Intellia Therapeutics stock opened at $22.93 on Friday. The firm has a 50 day moving average price of $23.34 and a 200-day moving average price of $24.24. Intellia Therapeutics, Inc. has a twelve month low of $19.21 and a twelve month high of $34.94. The company has a market capitalization of $2.21 billion, a P/E ratio of -4.28 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. The company’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same period last year, the business posted ($1.40) earnings per share. Equities analysts expect that Intellia Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.